Volume 70, Issue 4 (5 2012)                   Tehran Univ Med J 2012, 70(4): 236-241 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

N B, M S, A S, Z A, Gh A, B N. Effects of calcitonin nasal spray on serum bone resorptive marker CTX and other laboratory findings in osteopenic menopausal women: a clinical trial. Tehran Univ Med J. 2012; 70 (4) :236-241
URL: http://tumj.tums.ac.ir/article-1-124-en.html
1- , shohratimajid@yahoo.com
Abstract:   (8484 Views)

Background: Various therapeutic options such as calcitonin have been suggested for patients with low bone density, despite uncertain efficacy in most patients. C-telopeptide of type I collagen (CTX) is a new bone marker used for the assessment of bone resorption. The aim of this study was to evaluate the therapeutic effects of nasal spray calcitonin in women with osteopenia via serum CTX and other laboratory tests.

Methods: We conducted a self controlled clinical trial in 2009 on 105 women of menopausal age diagnosed in Baqiyatallah Hospital Clinic with osteopenia based on a bone mineral density score of 1.5 SD lower than peak bone mass. The patients were assigned to receive nasal spray calcitonin (200 IU/day), calcium (1000 mg/day) and Vit-D (400 IU/day) for 6 months. Serum CTX and other laboratory parameters were measured before and after the treatment. The data were analyzed by SPSS, version 17, using t-tests and a P<0.05 was considered statistically significant.

Results: Fifty-two patients completed the study and the mean CTX level decreased significantly from 3.10±2.03 to 2.61±1.82 pmol/lit (P<0.001), but total serum levels of PTH, Ca, AST, ALT and Alkaline Ph decreased insignificantly.

Conclusion: It seems that nasal spray of calcitonin is significantly effective in preventing disease progression and treatment of low bone density by inhibiting bone tissue resorption indicated by CTX although further studies with larger samples sizes and inclusion of control groups are warranted.

Full-Text [PDF 1609 kb]   (25761 Downloads)    

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 , Tehran University of Medical Sciences, CC BY-NC 4.0

Designed & Developed by : Yektaweb